ESMO 2019: Delegates told refractory metastatic renal cell carcinoma is an unmet need w... - 1 views
-
jacob logan on 17 Oct 19Despite advances in the renal cell carcinoma (RCC) therapy landscape, the majority of patients with RCC will eventually develop resistance to available therapies and the disease will progress through several stages, requiring further lines of treatment.